SEARCH

SEARCH BY CITATION

References

  • 1
    Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23:366371.
  • 2
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 1998; 282:103107.
  • 3
    Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antivir Ther 2000; 5:8590.
  • 4
    Layden JE, Layden TJ. Viral kinetics of hepatitis C: new insights and remaining limitations. Hepatology 2002; 35:967970.
  • 5
    Bergmann C, Layden JE, Levy-Drummer RS, Layden TJ, Haagmans BL, Neumann AU. Clinical implications of a new tri-phasic model of hepatitis C viral kinetics during IFN-alpha therapy. Hepatology 2001; 33(Suppl):345A.
  • 6
    Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226231.
  • 7
    Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120:14381447.
  • 8
    Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 1999; 30(Suppl):190A.
  • 9
    Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, Esteban R. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35:930936.
  • 10
    Di MW, Sallie R, Park Y, Yurdaydin C, Swain M, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:897903.
  • 11
    Bodenheimer GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473477.
  • 12
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:14261432.
  • 13
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:14851492.
  • 14
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958965.
  • 15
    Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160:34873493.
  • 16
    Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6:13751379.
  • 17
    Chung RT, He W, Saquib A, Contreras AM, Xavier RJ, Chawla A, Wang TC, et al. Hepatitis C virus replication is directly inhibited by IFN-α in a full-length binary expression system. Proc Natl Acad Sci U S A 2001; 98:98479852.
  • 18
    Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182:2835.
  • 19
    Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:16661672.
  • 20
    Fried MW, Shiffman ML, Reddy RK, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975982.
  • 21
    Doglio A, Laffont C, Caroli-Bosc FX, Rochet P, Lefebvre J. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 1999; 37:15671569.
  • 22
    Lee JH, Roth WK, Zeuzem S. Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays. J Hepatol 1997; 26:10011009.
  • 23
    Gosálvez J, Rodríguez-Iñigo E, Ramiro-Díaz JL, Bartomolé J, Tomás JF, Oliva H, Carreño V. Relative quantification and mapping of hepatitis C virus by in situ hybridization and digital image analysis. Hepatology 1998; 27:14281434.
  • 24
    Mann DV, Lam WWM, Hielm NM, So NMC, Yeung DKW, Metreweli C, Lau WY. Human liver regeneration: hepatic energy economy is less efficient when the organ is diseased. Hepatology 2001; 34:557565.
  • 25
    Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, Markowitz M, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999; 354:17821785.
  • 26
    Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680687.
  • 27
    Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395403.
  • 28
    Neumann AU, Dahari H, Conrad A, Plotz G, McHutchison JG. Early prediction and mechanism of the ribavirin/IFN-α dual therapy effect on chronic hepatitis C virus (HCV). Hepatology 1999; 30(Suppl):309A.
  • 29
    Pawlotsky JM, Dahari H, Conrad A, Lonjon I, Hezode C, Germanidis G, Schmid P, et al. Effect of intermittent interferon (IFN), daily IFN and IFN plus ribavirin induction therapy on hepatitis C virus (HCV) genotype 1b replication kinetics and clearance. Hepatology 1998; 28(Suppl):288A.
  • 30
    Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28:245252.
  • 31
    Berg T, Kaul T, Naumann U, Wiedenmann B, Hopf U. Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patients with response or no response. Z Gastroenterol 2000; 38:881886.
  • 32
    Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, Roth WK. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27:11491156.